Drug Delivery

Emerging controlled-release technologies could lead to more effective therapies in the near future.

Sharon Johnson, senior vice president, Global Quality & Regulatory Affairs, will head the organization.

Taste may be subjective, but it is crucial to patient compliance, particularly for pediatric treatments.

While the skin offers an alternative route of administration for local and systemic drug delivery, developing semi-solid dosage forms can be a challenge.

Bristol-Myers Squibb announced that it reached an agreement to acquire Flexus Biosciences and has entered into a $309-million partnership with Rigel Pharmaceuticals.

Celgene announced that its drug, Revlimid, gained FDA approval for the treatment of newly diagnosed multiple myeloma.

Sanofi launched a rapidly absorbed, short-acting inhalable insulin in the US to help control type 1 and type 2 diabetes.

Catalent Pharma Solutions and Sanofi-Aventis R&D have entered into a collaboration to develop Sanofi’s proprietary antibodies using Catalent’s SMARTag antibody drug conjugate (ADC) platform.

Mexichem announced that it acquired the distribution and sale license for HFC-227ea/P from Du Pont.

Tocophersolan or TPGS was developed 60 years ago as a water-soluble form of vitamin E. The author gives an overview of TPGS, including its interesting properties, examples found in the literature, and a brief summary of the regulatory status and marketed formulations.

This year’s Drug Delivery & Formulation Summit included discussions on solubility, drug penetration, and new approaches to technology.

Atlangram will have access to Carlina’s lipid nanocapsule technology platform Soludots under the terms of the agreement.

Merck announced an agreement with NewLink Genetics to acquire exclusive rights to its experimental Ebola vaccine, rVSV-EBOV, for $50 million.

ANSM wants company data on the benefits and risks of using Avastin over Lucentis in the treatment of wet age-related macular degeneration.

AstraZeneca announced a partnership with Pharmacyclics and Janssen for combination trials of MEDI4736 (AstraZeneca) with Imbruvica (Pharmacyclics and Janssen) for the treatment of hematologic cancers.

Spectranetics announced that it acquired Covidien's drug-coated balloon platform, Stellarex, for $30 million.

The author reviews the challenges in delivering macromolecule biologics.

Bristol-Myers Squibb announced that they have reached an agreement with F-star Alpha, giving BMS the exclusive option to acquire F-star's HER2-targeted breast and gastric cancer treatment.

Weighing the pros and cons of hot-melt extrusion and spray drying.

Formulation will utilize Catalent?s OSDrC OptiDose multicore drug-delivery platform.

Micronization and other processes are used to obtain optimal particle characteristics for pulmonary and oral solid-dosage delivery.

Innovations in drug delivery such as needle-free transfer devices and vial adapters can provide consistency when transferring liquid for reconstitution of lyophilized drug products.

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

The role of add-on devices and how they affect drug delivery with a pressurized metered dose inhaler.

Experts discuss developments and future trends in prefilled syringes.

PolySciTech's new launch, SpinSwiper, has the potential to speed up microparticle production.

Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.

Catalent's Advasept platform uses blow-fill-seal technology to aseptically manufacture, fill, and seal a polymeric primary container for injectable drugs.

Once an afterthought, packaging has now become an essential component of biopharmaceutical product development and marketing.

With the rising threat of antibiotic resistance and a diminishing R&D pipeline for novel drugs, Europe must step up its game to address this growing problem.